Abstract
An increasing volume of pre-clinical and clinical-translational research is attempting to identify novel biomarkers for improved diagnosis and risk-stratification of chemotherapy-induced cardiotoxicity. Most published animal models have employed weekly intraperitoneal injections of doxorubicin to reach a desired cumulative dose. This approach can be associated with severe systemic toxicity which limits the animal model usefulness, particularly for advanced imaging. In the current study, slow-release subcutaneous doxorubicin pellets demonstrated histopathologic evidence of cardiotoxicity at doses similar to standard human dose-equivalents without limiting animal survival or ability to participate in advanced imaging studies. This approach may provide a more robust cardiotoxicity animal model.
| Original language | English (US) |
|---|---|
| Journal | Cardiovascular Toxicology |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- Animal model
- Cardio-oncology
- Cardiotoxicity
- Chemotherapy
ASJC Scopus subject areas
- Molecular Biology
- Toxicology
- Cardiology and Cardiovascular Medicine
Cite this
}
Slow-Release Doxorubicin Pellets Generate Myocardial Cardiotoxic Changes in Mice Without Significant Systemic Toxicity. / Allen, Bradley D.; Zhang, Zhuoli; Naresh, Nivedita K.; Misener, Sol; Procissi, Daniele; Carr, James.
In: Cardiovascular Toxicology, 01.01.2019.Research output: Contribution to journal › Article
TY - JOUR
T1 - Slow-Release Doxorubicin Pellets Generate Myocardial Cardiotoxic Changes in Mice Without Significant Systemic Toxicity
AU - Allen, Bradley D.
AU - Zhang, Zhuoli
AU - Naresh, Nivedita K.
AU - Misener, Sol
AU - Procissi, Daniele
AU - Carr, James
PY - 2019/1/1
Y1 - 2019/1/1
N2 - An increasing volume of pre-clinical and clinical-translational research is attempting to identify novel biomarkers for improved diagnosis and risk-stratification of chemotherapy-induced cardiotoxicity. Most published animal models have employed weekly intraperitoneal injections of doxorubicin to reach a desired cumulative dose. This approach can be associated with severe systemic toxicity which limits the animal model usefulness, particularly for advanced imaging. In the current study, slow-release subcutaneous doxorubicin pellets demonstrated histopathologic evidence of cardiotoxicity at doses similar to standard human dose-equivalents without limiting animal survival or ability to participate in advanced imaging studies. This approach may provide a more robust cardiotoxicity animal model.
AB - An increasing volume of pre-clinical and clinical-translational research is attempting to identify novel biomarkers for improved diagnosis and risk-stratification of chemotherapy-induced cardiotoxicity. Most published animal models have employed weekly intraperitoneal injections of doxorubicin to reach a desired cumulative dose. This approach can be associated with severe systemic toxicity which limits the animal model usefulness, particularly for advanced imaging. In the current study, slow-release subcutaneous doxorubicin pellets demonstrated histopathologic evidence of cardiotoxicity at doses similar to standard human dose-equivalents without limiting animal survival or ability to participate in advanced imaging studies. This approach may provide a more robust cardiotoxicity animal model.
KW - Animal model
KW - Cardio-oncology
KW - Cardiotoxicity
KW - Chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=85065012423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065012423&partnerID=8YFLogxK
U2 - 10.1007/s12012-019-09521-0
DO - 10.1007/s12012-019-09521-0
M3 - Article
JO - Cardiovascular Toxicology
JF - Cardiovascular Toxicology
SN - 1530-7905
ER -